Article
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients.
Prostate cancer and prostatic diseases - 1 Jun 2026
Shore Neal D, Pieczonka Christopher M, Heron Sean, Gazi Mukaram, Cahn David J, Belkoff Laurence H, Berger Aaron D, Mazzarella Brian, Veys Joseph, Morris David, Bevan-Thomas Richard, Engelman Alexander, Dato Paul, Wise David R, Hardwick Mary Kay, Aradhya Kerry W, Heald Brandie, Nussbaum Robert L, Hatchell Kathryn E, Bucknor Brianna, Esplin Edward D, Nielsen Sarah M
Abstract excerpt
BACKGROUND: Although germline genetic testing can inform medical management for patients with prostate cancer (PCa), data are limited regarding patient-reported outcomes (PROs) after germline genetic testing for PCa. Recall and comprehension of germline genetic testing results, uptake of post-test clinical recommendations, and psychological impact of germline genetic testing among patients with PCa were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
